Goldman Sachs Call 3000 GVDBF 20..../ DE000GP772Y0 /
03.06.2024 9:56:29 | Изменение-0.15 | Бид17:39:18 | Предложение17:39:18 | Базовый актив | Цена исполнения | Дата истечения | Тип опциона |
---|---|---|---|---|---|---|---|
12.99EUR | -1.14% | 13.17 Величина цены спроса: 1,000 |
13.21 Величина цены предложения: 1,000 |
Givaudan SA | 3,000.00 - | 20.06.2025 | Call |
GlobeNewswire
17:53
Sustainable Green Team, Ltd. (SGTM) Signs Purchase Agreement to Acquire Patents and Intellectual Pro...
GlobeNewswire
17:35
Valneva Announces Publication of Lyme Disease Phase 2 Trials in the Lancet Infectious Diseases
GlobeNewswire
17:33
Natiivo Hospitality Expands with New South Florida Projects, Hires Yoav Gery as President
GlobeNewswire
17:30
Titan.ium Platform Announces Collaboration with Nokia Improving Security for Global Telecommunicatio...
GlobeNewswire
17:20
New CryptoStaking Strategies Introduced by CryptoHeap to Maximize Investor Returns
GlobeNewswire
17:15
DEADLINE ALERT for HRT and CKPT: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions...
GlobeNewswire
17:13
Los Angeles Student Wins NFTE West (Southern California) Youth Entrepreneurship Challenge
GlobeNewswire
17:12
Kirby McInerney LLP Reminds Harbor Diversified, Inc. (HRBR) Investors of Class Action Filing and Enc...
GlobeNewswire
17:11
Kirby McInerney LLP Reminds Global Cord Blood Corporation (CORBF) Investors of Upcoming Deadline in ...
GlobeNewswire
17:11
Infuse Summer Fun In Your Coffee With Bones Coffee Company’s New, Limited-Edition Summer Flavors
GlobeNewswire
17:02
Cambria Investment Management and Chesapeake Capital Corporation Announces the Launch of the Cambria...
GlobeNewswire
17:00
MidWestOne Financial Group Welcomes Three Key Executive Leaders to the Organization
GlobeNewswire
17:00
Zevra Therapeutics Announces Positive Final Results from Phase 2 Clinical Trial of KP1077 for Idiopa...
- Первая страница
- Назад
- 1
- 2
- 3
- 4
- Следующий
- Последняя страница